Appropriate targets for antibacterial drugs

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 12, 2016, Pages

  Silver, Lynn L ^a  

^a LL Silver Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ENZYME INHIBITOR; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENOME; CROSS RESISTANCE; DRUG EFFICACY; GENOMICS; NONHUMAN; BACTERIUM; CLASSIFICATION; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BACTERIA; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 85005982475     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a030239     Document Type: Article

References (36)

1. Black T, Hare R. 2000. Will genomics revolutionize antimicrobial drug discovery? Curr Opin Microbiol 3: 522–527.
2. Brotz-Oesterhelt H, Brunner NA. 2008. How many modes of action should an antibiotic have? Curr Opin Pharmacol 8: 564–573.
3. Brown DG, May-Dracka TL, Gagnon MM, Tommasi R. 2014. Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. J Med Chem 57: 10144–10161.
4. Chan PF, Macarron R, Payne DJ, Zalacain M, Holmes DJ. 2002. Novel antibacterials: A genomics approach to drug discovery. Curr Drug Targets Infect Disord 2: 291–308.
5. Chopra I. 2012. The 2012 Garrod Lecture: Discovery of antibacterial drugs in the 21st century. J Antimicrob Chemother 68: 496–505.
6. Erwin AL. 2016. Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme LpxC. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a025304.
7. Fernandes P. 2016. Fusidic acid: Abacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections. Cold Spring Harb Perspect Med 6: a025437.
8. Forsyth RA, Haselbeck RJ, Ohlsen KL, Yamamoto RT, Xu H, Trawick JD, Wall D, Wang L, Brown-Driver V, Froelich JM, et al. 2002. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol 43: 1387–1400.
9. Gadebusch HH, Stapley EO, Zimmerman SB. 1992. The discovery of cell wall active antibacterial antibiotics. Crit Rev Biotechnol 12: 225–243.
10. Garcia-Contreras R, Maeda T, Wood TK. 2015. Can resistance against quorum-sensing interference be selected? ISME J 10: 4–10.
11. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. 2010. Challenges of antibacterial discovery revisited. Ann NY Acad Sci 1213: 5–19.
12. Isaacson RE. 2002. Genomics and the prospects for the discovery of new targets for antibacterial and antifungal agents. Curr Pharm Des 8: 1091–1098.
13. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. 2012. Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67: 255–268.
14. Lange RP, Locher HH, Wyss PC, Then RL. 2007. The targets of currently used antibacterial agents: Lessons for drug discovery. Curr Pharm Des 13: 3140–3154.
15. Lerner CG, Beutel BA. 2002. Antibacterial drug discovery in the post-genomics era. Curr Drug Targets Infect Disord 2: 109–119.
16. Livermore DM. 2006. Can β-lactams be re-engineered to beat MRSA? Clin Microbiol Infect 12: 11–16.
17. Livermore DM. 2011. Discovery research: The scientific challenge of finding new antibiotics. J Antimicrob Chemother 66: 1941–1944.
18. Maeda T, Garcia-Contreras R, Pu M, Sheng L, Garcia LR, Tomas M, Wood TK. 2012. Quorum quenching quandary: Resistance to antivirulence compounds. ISME J 6: 493–501.
19. McDevitt D, Payne DJ, Holmes DJ, Rosenberg M. 2002. Novel targets for the future development of antibacterial agents. J Appl Microbiol 92: 28S–34S.
20. Mills SD. 2006. When will the genomics investment pay off for antibacterial discovery? Biochem Pharmacol 71: 1096–1102.
21. Mills SD, Dougherty TJ. 2012. Cell-based screening in antibacterial discovery. In Antibiotic discovery and development (ed. Dougherty JT, Pucci JM), pp. 901–929. Springer, Boston.
22. Monaghan RL, Barrett JF. 2006. Antibacterial drug discovery— Then, now and the genomics future. Biochem Pharmacol 71: 901–909.
23. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 47: 2850–2858.
24. O’Dwyer K, Spivak A, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan A, Livi GP, Sathe G, et al. 2014. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother 59: 289–298.
25. Overbye KM, Barrett JF. 2005. Antibiotics:Where did we go wrong? Drug Discov Today 10: 45–52.
26. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29–40.
27. Projan SJ. 2002. New (and not so new) antibacterial targets— From where and when will the novel drugs come? Curr Opin Pharmacol 2: 513–522.
28. Ruer S, Pinotsis N, Steadman D, Waksman G, Remaut H. 2015. Virulence-targeted antibacterials: Concept, promise, and susceptibility to resistance mechanisms. Chem Biol Drug Des 86: 379–399.
29. Schmid MB, Kapur N, Isaacson DR, Lindroos P, Sharpe C. 1989. Genetic analysis of temperature-sensitive lethal mutants of Salmonella typhimurium. Genetics 123: 625–633.
30. Silver LL. 2007. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6: 41–55.
31. Silver LL. 2011. Challenges of antibacterial discovery. Clin Microbiol Rev 24: 71–109.
32. Silver LL. 2012. Rational approaches to antibacterial discovery: Pre-genomic directed and phenotypic screening. In Antibiotic discovery and development (ed. Dougherty TJ, Pucci MJ), pp. 33–75. Springer, Boston.
33. Silver LL, Bostian KA. 1993. Discovery and development of new antibiotics: The problem of antibiotic resistance. Antimicrob Agents Chemother 37: 377–383.
34. Singh SB, Young K, Miesel L. 2011. Screening strategies for discovery of antibacterial natural products. Expert Rev Anti Infect Ther 9: 589–613.
35. Tommasi R, Brown DG, Walkup GK, Manchester JI, Miller AA. 2015. ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 14: 529–542
36. Yao J, Rock CO. 2016. Resistance mechanisms and the future of bacterial enoyl-acyl carrier protein reductase (FabI) antibiotics. Cold Spring Harb Perspect Med 6: a027045.